QUEBEC, Oct. 29 /PRNewswire/ -- The Fondation du Centre hospitalier universitaire de Sherbrooke (CHUS) is proud to announce that Waters Corporation has donated a Waters(R) Synapt(TM) MS System, the latest generation of mass spectrometers. This gift -- worth a total C$1.1 million -- is the result of a partnership between Waters and CHUS which is critical to the creation of the Centre d'expertise en spectrometrie de masse clinique Waters-CHUS (Waters-CHUS Expertise Center for Clinical Mass Spectrometry) for screening, clinical diagnosis, and assessment of treatments for specific hereditary diseases, as well as for patient surveillance and management.
CHUS formally acknowledged the donation made by Waters Corporation at a ceremony officially inaugurating the laboratory.
The acquisition of this state-of-the-art technology and establishment of the center will enable the CHUS to sustain its position at the cutting edge of genetics in detecting hereditary metabolic diseases and in research into assessing metabolites for various other diseases. The device is in addition to the acquisition of the first mass spectrometer -- a Waters Quattro(TM) micro - - made possible by the Fondation du CHUS in 2005. At that time, the CHUS had the distinction of being Quebec's first university hospital to put this technology to use in a clinical setting.
The Centre d'expertise en spectrometrie de masse clinique Waters-CHUS will come under the direction of biochemist Christiane Auray-Blais, PhD, researcher with the mother-child thrust of the CHUS Centre de recherche clinique Etienne- Le Bel, and professor in the Faculty of Medicine and Health Sciences at the Universite de Sherbrooke.
"Patients will be the first to benefit from this unique partnership,
since it will make new clinical tests available to the public. This mass
spectrometer will enable us to identify previously unknown biomarkers, that
is, characteristics that can be objectively measured biochemi
|SOURCE Sherbrooke Hospital|
Copyright©2008 PR Newswire.
All rights reserved